Sarepta Therapeut…
USUSDSarepta Therapeutics Inc (US:SRPT) — Biotechnology: Pharmaceutical Preparations. Število borz, na katerih se trgujejo delnice družbe: 2. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.
O Podjetju
- Spletna Stran
- sarepta.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sedež
- Cambridge, United States
- Izvršni Direktor
- Michael E. Severino
- Zaposleni
- 835
- Ustanovljena
- 1980
- Delnice v Obtoku
- 105.63 mio. na dan 2026-07-31
- Prosto Prenosljive Delnice
- 100.54 mio.
- Tržna Kapitalizacija
- 1.86 mrd. USD
- Notranje Osebe
- 4.89%
- Institucionalni Vlagatelji
- 104.07%
- Panoga (SIC)
- Pharmaceutical Preparations
- ISIN
- US8036071004
- LEI
- 549300IKDPIED8J8IG21
- FCF
- 81.8 mio. USD
- Dolg
- 848 mio. USD3.4 let FCF
- Dobiček in FCF — za 12 mesecev do 30.06.2026 (najnovejše poročilo podjetja).
Opis
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Največji Imetniki
| Imetnik | Delež | Delnice | Datum Poročila |
|---|---|---|---|
| Blackrock Inc. | 17.98% | 18.99 mio. | 2026-06-30 |
| State Street Corporation | 8.44% | 8.92 mio. | 2026-06-30 |
| Vanguard Portfolio Manag… | 7.93% | 8.38 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 6.09% | 6.44 mio. | 2026-08-31 |
| First TRT Exch-Trd Fd.-F… | 4.52% | 4.78 mio. | 2026-08-31 |
| SPDR SERIES TRUST-State… | 4.45% | 4.7 mio. | 2026-08-31 |
| Two Sigma Investments, L… | 4.35% | 4.6 mio. | 2026-06-30 |
| Vanguard Capital Managem… | 4.35% | 4.59 mio. | 2026-06-30 |
| First Trust Advisors LP | 4.13% | 4.37 mio. | 2026-06-30 |
| AQR Capital Management,… | 4.1% | 4.33 mio. | 2026-06-30 |
| BARRY RICHARD J (Directo… | ≈3.06% | 3.23 mio. | 2026-06-04 |
| VANGUARD INDEX FUNDS-Van… | 3.02% | 3.19 mio. | 2026-06-30 |
| Geode Capital Management… | 2.62% | 2.77 mio. | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.52% | 2.66 mio. | 2026-08-31 |
| Erste Asset Management G… | 2.43% | 2.57 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.17% | 2.3 mio. | 2026-06-30 |
| Marshall Wace LLP | 2.09% | 2.21 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.26% | 1.33 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.14% | 1.2 mio. | 2026-06-30 |
| Fidelity Salem Street Tr… | 1.08% | 1.14 mio. | 2026-07-31 |
| Federated Hermes Equity… | 1.05% | 1.11 mio. | 2026-07-31 |
| INGRAM DOUGLAS S (Chief… | ≈0.88% | 929 391 | 2025-12-05 |
| SEVERINO MICHAEL E (Chie… | ≈0.72% | 756 104 | 2026-07-28 |
| CHAMBERS MICHAEL ANDREW… | ≈0.48% | 504 027 | 2026-06-04 |
| RODINO-KLAPAC LOUISE (Of… | ≈0.22% | 227 670 | 2026-02-27 |
| BEHRENS M KATHLEEN (Dire… | ≈0.21% | 224 357 | 2026-06-04 |
| ESTEPAN IAN MICHAEL (Chi… | ≈0.19% | 204 699 | 2026-02-27 |
| ROTHFUSS CRISTIN (Genera… | ≈0.13% | 139 985 | 2025-09-03 |
| WONG RYAN HO-YAN (Chief… | ≈0.13% | 136 203 | 2025-09-03 |
| NICAISE CLAUDE (Director… | ≈0.05% | 48 407 | 2026-06-04 |
Prijavite se z Google